BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

466 related articles for article (PubMed ID: 36471232)

  • 1. Metabolic associated fatty liver disease better identifying patients at risk of liver and cardiovascular complications.
    Cheng YM; Wang CC; Kao JH
    Hepatol Int; 2023 Apr; 17(2):350-356. PubMed ID: 36471232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of concomitant hepatitis C virus infection on liver and cardiovascular risks in patients with metabolic-associated fatty liver disease.
    Tsai PS; Cheng YM; Wang CC; Kao JH
    Eur J Gastroenterol Hepatol; 2023 Nov; 35(11):1278-1283. PubMed ID: 37773778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence and clinical outcomes in subtypes of metabolic associated fatty liver disease.
    Cheng KL; Wang SW; Cheng YM; Hsieh TH; Wang CC; Kao JH
    J Formos Med Assoc; 2024 Jan; 123(1):36-44. PubMed ID: 37491179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of HBV infection on clinical outcomes in patients with metabolic dysfunction-associated fatty liver disease.
    Cheng YM; Hsieh TH; Wang CC; Kao JH
    JHEP Rep; 2023 Sep; 5(9):100836. PubMed ID: 37600956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic dysfunction-associated fatty liver disease improves detection of high liver stiffness: The Rotterdam Study.
    van Kleef LA; Ayada I; Alferink LJM; Pan Q; de Knegt RJ
    Hepatology; 2022 Feb; 75(2):419-429. PubMed ID: 34453359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Noninvasive fibrosis tools in NAFLD: validation of APRI, BARD, FIB-4, NAFLD fibrosis score, and Hepamet fibrosis score in a Portuguese population.
    Rigor J; Diegues A; Presa J; Barata P; Martins-Mendes D
    Postgrad Med; 2022 May; 134(4):435-440. PubMed ID: 35332833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-invasive Screening of Metabolic Associated Fatty Liver Disease and Affecting Factors in Primary Care.
    Balci IC; Haciagaoglu N; Oner C; Cetin H; Simsek EE
    J Coll Physicians Surg Pak; 2023 Apr; 33(4):390-395. PubMed ID: 37190709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Associations of metabolic dysfunction-associated fatty liver disease and hepatic fibrosis with bone mineral density and risk of osteopenia/osteoporosis in T2DM patients.
    Zhang W; Li Y; Li S; Zhou J; Wang K; Li Z; Chen N; Chen X
    Front Endocrinol (Lausanne); 2023; 14():1278505. PubMed ID: 38116314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibrosis-4 Index Score Predicts Concomitant Coronary Artery Diseases Across the Spectrum of Fatty Liver Disease.
    McNally BB; Rangan P; Wijarnpreecha K; Fallon MB
    Dig Dis Sci; 2023 Sep; 68(9):3765-3773. PubMed ID: 37392337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of NAFLD and MAFLD diagnostic criteria in contemporary urban healthy adults in China: a cross-sectional study.
    Liu Q; Zhao G; Li Q; Wu W; Zhang Y; Bian H
    BMC Gastroenterol; 2022 Nov; 22(1):471. PubMed ID: 36402947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic dysfunction associated fatty liver disease identifies subjects with cardiovascular risk better than non-alcoholic fatty liver disease.
    Chun HS; Lee M; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Lee YH; Kim JH; Kim SU
    Liver Int; 2023 Mar; 43(3):608-625. PubMed ID: 36585250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic (Dysfunction)-Associated Fatty Liver Disease in Chinese Patients with Type 2 Diabetes from a Subcenter of the National Metabolic Management Center.
    Guan C; Fu S; Zhen D; Yang K; An J; Wang Y; Ma C; Jiang N; Zhao N; Liu J; Yang F; Tang X
    J Diabetes Res; 2022; 2022():8429847. PubMed ID: 35127953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A significant risk of metabolic dysfunction-associated fatty liver disease plus diabetes on subclinical atherosclerosis.
    Bessho R; Kashiwagi K; Ikura A; Yamataka K; Inaishi J; Takaishi H; Kanai T
    PLoS One; 2022; 17(5):e0269265. PubMed ID: 35639744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
    Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
    Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MAFLD might be better in identifying subjects with sarcopenia or cardiovascular risk than NAFLD: A nationwide study.
    Han E; Chun HS; Lee YH; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Lee BW; Kang ES; Cha BS; Ahn SH; Kim SU
    J Gastroenterol Hepatol; 2023 Sep; 38(9):1598-1609. PubMed ID: 37321651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibrotic Burden in the Liver Differs Across Metabolic Dysfunction-Associated Fatty Liver Disease Subtypes.
    Lim TS; Chun HS; Kim SS; Kim JK; Lee M; Cho HJ; Kim SU; Cheong JY
    Gut Liver; 2023 Jul; 17(4):610-619. PubMed ID: 36799062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of diagnostic performance between FIB-4 and NFS in metabolic-associated fatty liver disease era.
    Park H; Yoon EL; Kim M; Lee J; Kim JH; Cho S; Jun DW; Nah EH
    Hepatol Res; 2022 Mar; 52(3):247-254. PubMed ID: 34841632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new risk stratification strategy for fatty liver disease by incorporating MAFLD and fibrosis score in a large US population.
    Zhang YC; Lyu ZY; Ma B; Li LM; Wang W; Sheng C; Dai HJ; Huang YB; Song FF; Song FJ; Chen KX
    Hepatol Int; 2022 Aug; 16(4):835-845. PubMed ID: 35701716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibrotic Burden Determines Cardiovascular Risk among Subjects with Metabolic Dysfunction-Associated Fatty Liver Disease.
    Han E; Lee YH; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Lee BW; Kang ES; Cha BS; Kim SU
    Gut Liver; 2022 Sep; 16(5):786-797. PubMed ID: 35321955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic-associated fatty liver disease in relation to site-specific and multiple-site subclinical atherosclerosis.
    Wang X; Zhang R; Man S; Lv J; Yu C; Yin J; Wang X; Deng Y; Wang B; Li L; Pang Y
    Liver Int; 2023 Aug; 43(8):1691-1698. PubMed ID: 37337780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.